Other Consolidated Financial Statement Detail (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012
Other Income (Expense), Net
Interest income	$ 900,000	$ 10,200,000	$ 5,200,000	$ 16,700,000
Interest expense	(7,300,000)	(7,000,000)	(18,900,000)	(14,400,000)
Impairment of investments	(1,400,000)	(800,000)	(1,700,000)	(1,300,000)
Gain (loss) on sales of investments, net	5,700,000	2,500,000	10,100,000	14,300,000
Foreign exchange gains (losses), net	(5,300,000)	(1,300,000)	(7,900,000)	100,000
Other, net	(3,000,000)	(600,000)	(11,700,000)	2,700,000
Total other income (expense), net	(10,428,000)	2,950,000	(24,885,000)	18,094,000
Accrued Expenses and Other
Revenue-related rebates	218,600,000		218,600,000		191,000,000
Employee-related Liabilities	213,300,000		213,300,000		248,500,000
Deferred revenue	167,400,000		167,400,000		148,000,000
Royalties and licensing fees	113,500,000		113,500,000		45,200,000
Clinical development expenses	54,500,000		54,500,000		51,600,000
Production expenses accrual	42,500,000		42,500,000		45,600,000
Construction in progress accrual	29,300,000		29,300,000		12,300,000
Current portion of contingent consideration obligations	27,900,000		27,900,000		22,400,000
Collaboration expenses	25,900,000		25,900,000		37,400,000
Other	163,300,000		163,300,000		177,900,000
Total accrued expenses and other	$ 1,056,229,000		$ 1,056,229,000		$ 979,945,000